Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
3-3 μM) dose-dependently reduces the migration of cells induced by growth factors (PDGF-BB
550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection
110(33):13594-9
5-10 µM in vitro and cellular assays
GSK256066 (10 μg/kg) is administered intratracheally at different times (2
Tivantinib previr 3-3 μM) dose-dependently reduces theTivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c Met with potential antineoplastic activity. c Met inhibitor ARQ 197 binds to the c Met protein and disrupts c Met signal transduction pathways, which may induce cell death in tumor cells overexpressing c Met protein or expressing consitutively activated c Met protein. c Met protein, the product of the proto oncogene c Met, is a receptor tyrosine kinase also known as
US$ 29.99
US$ 2544.00
US$ 44.95